Form D · Other

Biosign Technologies Inc

Thornhill, A6 · CIK 0001328155

Offering snapshot reported Aug 9, 2011 · SEC filing

Reported sold: $231K
Investors reported: 2
Minimum accepted: $0
First sale: Jul 27, 2011

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Aug 9, 2011	Initial	$231,367	No comparison	2	SEC filing
Nov 18, 2010	Initial	$1,801,029	No comparison	5	SEC filing
May 18, 2005	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-164126

Each unit consists of 1 common share and one common share purchase warrant. Each whole warrant entitles the holder to acquire 1 common share at an approximate price of $1.00 until July 27, 2012.

Source: Form D, filed Aug 9, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
John Anders	Executive
Colley Clarke	Executive
Alfonse D'amato	Director
Scott Jenkins	Executive
Harold S. Koplewicz	Director
Tony La Vista	Director
Eva Kettle Leca	Executive
Radu Leca	Director, Executive
Jason Meretsky	Director
Mouane Sengsavang	Director, Executive
Raffi Sethian	Executive
David M. Silver	Director
Christian Sleight	Executive
Peter Tassiopoulos	Executive

Issuer details

Industry: Other (See others in industry)

Address:

175 Commerce Valley Drive West Suite 230
Thornhill, A6, L3T 7P6